venlafaxine / Generic mfg. - LARVOL DELTA

Examining individual serotonin and norepinephrine reuptake inhibitors and fall-related hospitalizations in older adults. (PubMed, Ment Health Clin) - "Data were drawn from Merative MarketScan Medicare Supplemental claims (January 1, 2015 to November 30, 2021), including adults 65 years and older prescribed an SNRI (ie, duloxetine, venlafaxine, desvenlafaxine, milnacipran, levomilnacipran). Venlafaxine appears to have a lower fall risk than duloxetine. Further studies are needed to determine clinical significance and assess fall-related costs to support safer SNRI use in older adults."

Journal • Geriatric Disorders

The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database. (PubMed, Front Pharmacol) - "This pharmacovigilance analysis systematically identified significant safety signals associated with venlafaxine. The findings provide important evidence to support safer clinical use of venlafaxine and may assist in optimizing individualized therapeutic decisions in practice."

Adverse events • Journal • P4 data • Real-world evidence • Cardiovascular • CNS Disorders • Depression • Immunology • Major Depressive Disorder • Mood Disorders • Nephrology • Psychiatry • Renal Disease

Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial. (PubMed, Breast Cancer) - No abstract available

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

A community-guided approach to monitoring contaminants of emerging concern in freshwater systems using passive samplers. (PubMed, NPJ Emerg Contam) - "A total of 51 CECs were quantified in the water and passive sampler extracts, with ketamine, lidocaine, tramadol, and venlafaxine occurring in over 50% of samples. They identified key areas for improving the field deployment procedure and the data collection system. This work demonstrates the applicability of the 3D-PSD to large-scale citizen science and other community engagement projects for freshwater monitoring."

Journal

Prediction of 12-Week Remission in Patients With Depressive Disorder Using Reasoning-Based Large Language Models: Model Development and Validation Study. (PubMed, JMIR Ment Health) - "We analyzed data from 390 patients in the MAKE Biomarker discovery study who were undergoing first-step antidepressant monotherapy with 12 different medications, including escitalopram, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, milnacipran, mirtazapine, bupropion, vortioxetine, tianeptine, and trazodone, after excluding those with uncommon medications (n=9) or missing biomarker data (n=32). Clinical evaluation by psychiatrists showed favorable mean ratings for correctness (4.3, SD 0.7), consistency (4.2, SD 0.8), specificity (4.2, SD 0.7), helpfulness (4.2, SD 1.0), and human likeness (3.6, SD 1.7) on 5-point scales. These findings demonstrate that reasoning-based LLMs, particularly when enhanced with research-informed prompting, show promise for predicting antidepressant response and could serve as interpretable adjunctive tools in depressive disorder treatment planning, although prospective validation in real-world clinical settings remains..."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Construction and clinical application verification of venlafaxine antidepressant efficacy prediction model based on multi-omics integration analysis (ChiCTR) - P=N/A | N=600 | Not yet recruiting | Sponsor: Affiliated Kangning Hospital of Ningbo University; Affiliated Kangning Hospital of Ningbo University

New trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

Drug-related suicidal events in children and teenagers: Age-stratified insights from FAERS. (PubMed, Leg Med (Tokyo)) - "Across FAERS youth suicide reports, drug-associated fatality risk varies markedly by drug, surges in mid- to late adolescence, diverges by sex and shifts at both age extremes. These heterogeneities underscore the need for age-appropriate pharmacovigilance and trial strategies rather than direct extrapolation from adult data, particularly regarding the safety of drugs associated with suicide."

Journal • Pediatrics

Venlafaxine-Associated Takotsubo Cardiomyopathy Complicated by Cardiogenic Shock and Left Ventricular Outflow Tract Obstruction: A Case Report and Literature Review. (PubMed, Acta Cardiol Sin) - No abstract available

Journal • Cardiomyopathy • Cardiovascular

Case Report: Prolonged DAWS in an RLS patient under severe relational stress. (PubMed, Front Hum Neurosci) - "While DAWS is classically associated with high-dose dopamine agonists (DAs) in Parkinson's disease, it has also been reported in RLS patients treated with low-dose therapy (≤ 0.75 mg pramipexole equivalent), although such cases remain rare...A 6-month venlafaxine taper, completed 2 weeks before DA tapering, may have increased neurochemical vulnerability...This factor may need to be systematically assessed in DAWS management. As a rare patient-authored account, this report contributes to the understanding of DAWS in non-PD populations and highlights the need for longitudinal research to guide safer withdrawal protocols and integrated care."

Journal • CNS Disorders • Fatigue • Immunology • Movement Disorders • Pain • Parkinson's Disease • Restless Legs Syndrome • Sleep Disorder

The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia (clinicaltrials.gov) - P=N/A | N=106 | Recruiting | Sponsor: Beijing Tiantan Hospital | N=400 ➔ 106

Enrollment change • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

The Analgesic Efficacy and Safety of Venlafaxine in Patients With Herpes Zoster (clinicaltrials.gov) - P=N/A | N=750 | Recruiting | Sponsor: Beijing Tiantan Hospital

New trial • Herpes Zoster • Pain • Varicella Zoster

Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache (clinicaltrials.gov) - P=N/A | N=432 | Active, not recruiting | Sponsor: Tongji Hospital

New trial • Pain

Verapamil and venlafaxine combined as an effective and well-tolerated adjunct for cancer pain management. (PubMed, Am J Transl Res) - "Compared with verapamil alone, combined therapy of verapamil and venlafaxine significantly relieves pain, improves psychological outcomes, and enhance patients' quality of life without increasing adverse events. These findings support its potential as an effective and well-tolerated adjunctive strategy for cancer pain management."

Journal • CNS Disorders • Depression • General Anxiety Disorder • Mood Disorders • Oncology • Pain • Psychiatry

Patient treatment preference as a predictor of clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and nonresponders with treatment-resistant depression (ASCERTAIN-TRD). (PubMed, Int Clin Psychopharmacol) - P4 | "This is a secondary analysis investigating the relationship between treatment preference and response to treatment in the antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) trial (NCT02977299) comparing three treatment arms [aripiprazole augmentation, repetitive transcranial magnetic stimulation (rTMS) augmentation, switching to venlafaxine XR or duloxetine] in MDD patients with treatment-resistant depression (TRD) who are currently on ongoing, stable, and adequate antidepressant therapy. In the total population, participants' preferences did not affect their response to treatment, and the change in MADRS score was similar among patients who received their preferred treatment, had no preference, or received treatment against their preference (P = 0.49). These results indicate that patient preference is not a significant factor that predisposes to optimal treatment outcomes."

Clinical data • HEOR • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Evaluating efficacy of pregabalin in diabetic peripheral neuropathy pain management. (PubMed, Korean J Pain) - "Search terms included "pregabalin," "diabetic," "peripheral," "neuropathy," and "pain." Experimental groups varied from amitriptyline, duloxetine, carbamazepine, venlafaxine, and Xiaoketongbi Formula (XF). In terms of adverse effects, pregabalin was more tolerated among patients, though side effects were generally mild. Pregabalin remains an effective option for DPN pain management and is considered noninferior to current monotherapies and combination therapies."

Journal • Review • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain

Venlafaxine-induced serotonin syndrome causing bilateral cerebral strokes: a case report. (PubMed, Front Stroke) - "A 21-year-old Caucasian woman was admitted to our neurologic intermediate care unit after attempting suicide by ingesting an estimated 15 g venlafaxine (Trevilor retard®), adding up to a serum concentration of approximately 17,943 μg/l. Furthermore, we aim to increase awareness of hypoglycemia and epileptic seizures as complications of venlafaxine intoxication. In addition, we demonstrate important pitfalls in the diagnostic procedure and propose a treatment regimen for the underlying serotonin syndrome."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Hypoglycemia • Ischemic stroke • Psychiatry

TNA-LBP: Treating Negative Affect in Low Back Pain Patients (clinicaltrials.gov) - P2/3 | N=308 | Completed | Sponsor: Ajay Wasan, MD, Msc | Active, not recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ Dec 2025

Trial completion • Trial completion date • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

MDD: Neurobiological and Genomic Predictors of Relapse in Depression (clinicaltrials.gov) - P=N/A | N=204 | Recruiting | Sponsor: Mehmet Kemal Arikan

New trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

EVALUATION OF THE THERAPEUTIC EFFECTS OF DIFFERENT DOSES OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF DEPRESSION IN PARKINSON (ADPD 2026) - "Both 50U and 100U BoNT/A demonstrate antidepressant effects comparable to venlafaxine in PD patients. The lower 50U dose may be preferable as a treatment option."

CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Comparative effects of antidepressants on cocaine-induced hyperthermia in rats: a preclinical study. (PubMed, Neurosci Lett) - "Mirtazapine may be a safer antidepressant option for managing depression in cocaine users because of its capacity to suppress hyperthermia without enhancing monoamine reuptake inhibition. Notably, caution should be exercised when prescribing monoamine oxidase inhibitors and SNRIs to this population. However, further clinical studies are required to validate these findings."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry

Sublingual cyclobenzaprine (Tonmya) for fibromyalgia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

Electronic Structure and Redox of the Antidepressants Venlafaxine and Desvenlafaxine. (PubMed, ACS Omega) - "The Gibbs free energy variations in different medium environments revealed the critical role of the medium in modulating the thermodynamic stability. These findings presented here improve our understanding of the electrochemical and electronic properties of these antidepressants and may pave the way for the development of more effective therapeutic agents."

Journal

Migraine worsening after excellent initial response to galcanezumab (EHF-EHC 2025) - "Several prophylactics were tried (topiramate, amitriptyline, and atogepant) with no improvement...However, in the last few months of treatment, she experienced recrudescence of symptoms – she's now awaiting treatment with eptinezumab...While he tried several preventive medications (topiramate, amitriptyline, venlafaxine and valproic acid), he was also medicated with corticosteroids... Recent literature and medical experience refer to Galcanezumab as a good sustained treatment to refractory migraine. However, these cases highlight the situations in which, despite the initial response being great, there's no prolonged effect on pain relief."

Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Hepatology • Hereditary Angioedema • Migraine • Pain

Middle meningeal artery lidocaine infusion for refractory migraine: First case report in Portugal (EHF-EHC 2025) - "Various pharmacologic classes were tried without benefit: antihypertensives and calcium channel blockers (propranolol, candesartan, flunarizine), antiepileptics (valproic acid, topiramate, oxcarbazepine), antidepressants (amitriptyline, nortriptyline, venlafaxine, fluvoxamine, sertraline, clomipramine), other preventives (prednisolone, oxitriptan, melatonin), cycles of botulinum toxin (PREEMPT protocol), monoclonal antibodies (galcanezumab, fremanezumab, erenumab), and atogepant. At the time of the procedure, the patient was on eptinezumab 100 mg and botulinum toxin every three months but continued to have daily headaches, with severe intensity and reliance on eletriptan for acute relief... MMA lidocaine infusion has been described in few cases, and this is, to our knowledge, the first reported in Portugal. It constitutes an invasive therapeutic approach that should be considered only as a rescue option for carefully selected patients with severely refractory migraine...."

Case report • Clinical • Anorexia • CNS Disorders • Migraine • Pain

Comparative efficacy and safety of venlafaxine versus amitriptyline for migraine prophylaxis: A systematic review and meta-analysis (EHF-EHC 2025) - "Venlafaxine demonstrated superior efficacy in reducing migraine frequency compared to amitriptyline, while both treatments demonstrated comparable efficacy in reducing migraine severity and duration. Safety profiles were similar, suggesting venlafaxine may be a clinically appropriate alternative for migraine prophylaxis. Further trials are needed to confirm these findings."

Retrospective data • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain • Xerostomia